Bachrodt Amy's Form 4 filing
Maze Therapeutics, Inc.MAZE · filed Dec 31, 2025
- Accession no.
- 0002050422-25-000007
- Filed
- Dec 31, 2025
- Trade date
- Dec 29-30, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 7 non-derivative transactions and 4 derivative transactions. Open-market sales total $606.2K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bachrodt AmyCIK 0002050422 | Officer (SVP, Finance) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 29, 2025 | Common Stock | MOption exerciseAcquired | +124 | $10.42 | +$1,292.08 | 13,089 | Direct | |
| Dec 29, 2025 | Common Stock | MOption exerciseAcquired | +9,876 | $10.42 | +$102,907.92 | 22,965 | Direct | |
| Dec 29, 2025 | Common Stock | SSaleDisposed | −9,400 | $40.54F2 | −$381,076 | 13,565 | Direct | |
| Dec 29, 2025 | Common Stock | SSaleDisposed | −600 | $41.16F3 | −$24,696 | 12,965 | Direct | |
| Dec 30, 2025 | Common Stock | MOption exerciseAcquired | +2,395 | $10.42 | +$24,955.9 | 15,360 | Direct | |
| Dec 30, 2025 | Common Stock | MOption exerciseAcquired | +2,605 | $10.42 | +$27,144.1 | 17,965 | Direct | |
| Dec 30, 2025 | Common Stock | SSaleDisposed | −5,000 | $40.08F4 | −$200,400 | 12,965 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 29, 2025 | Common Stock | MOption exerciseDisposed | −124 | $0.00 | $0 | 2,396 | Direct | |
| Dec 29, 2025 | Common Stock | MOption exerciseDisposed | −9,876 | $0.00 | $0 | 23,834 | Direct | |
| Dec 30, 2025 | Common Stock | MOption exerciseDisposed | −2,395 | $0.00 | $0 | 1 | Direct | |
| Dec 30, 2025 | Common Stock | MOption exerciseDisposed | −2,605 | $0.00 | $0 | 2,581 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.04 to $40.94 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4.
Referenced by the price of 1 transaction in Table I.
- F3
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.04 to $41.29 per share, inclusive.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.36 per share, inclusive.
Referenced by the price of 1 transaction in Table I.